ISSN: 1175-3277
Journal Home
Journal Guideline
American Journal of Cardiovascular Drugs Q2 Unclaimed
American Journal of Cardiovascular Drugs is a journal indexed in SJR in Medicine (miscellaneous) and Cardiology and Cardiovascular Medicine with an H index of 57. It has a price of 3190 €. It has an SJR impact factor of 0,841 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,841.
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
3190 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
0,841
SJR Impact factor57
H Index63
Total Docs (Last Year)177
Total Docs (3 years)2606
Total Refs524
Total Cites (3 years)168
Citable Docs (3 years)3.12
Cites/Doc (2 years)41.37
Ref/DocOther journals with similar parameters
Seizure : the journal of the British Epilepsy Association Q2
Genes to Cells Q2
Acta Neurologica Scandinavica Q2
Clinical Rheumatology Q2
Annals of Global Health Q2
Compare this journals
Aims and Scope
Best articles by citations
Role of Metabolically Active Drugs in the Management of Ischemic Heart Disease
View moreAortic Insufficiency
View moreIdarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience
View moreReduction of Serum LDL-C Levels
View morePrevention of Restenosis with Antioxidants
View moreThe Sirolimus-Eluting Stent
View moreClinical Experience with Perindopril in Elderly Hypertensive Patients
View moreThe new European Guidelines in Hypertension
View moreRisk of Suicide in Users of Cardiovascular Drugs
View moreExploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches
View moreHIV-Related Cardiovascular Disease and Drug Interactions
View moreCould Influenza Vaccination Prevent Myocardial Infarction, Stroke and Sudden Cardiac Death?
View moreModified-Release Formulation of Trimetazidine for Exceptional Control of Angina Pectoris
View moreNew strategies for hypertension control
View moreImproving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol
View morePhotopheresis
View moreDevelopment of Radiocontrast Agents for Vascular Imaging
View morePharmacologic Rationale for Trimetazidine in the Treatment of Ischemic Heart Disease
View moreRenal protection
View moreTherapeutic Effects of Angiotensin (AT1) Receptor Antagonists
View moreMedical Management of Chronic Heart Failure in Children
View moreCarnitine Palmitoyltransferase-I, a New Target for the Treatment of Heart Failure
View morePharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients
View moreCalcium Channel Antagonists in the Treatment of Hypertension
View more
Comments